



Forward Edge, Inc.
1209 Genoa Red Bluff,
Pasadena, Tx 77504
Phone: (713) 920-1335
Email: feireporting@forwardedgeinc.com



TO: DOT POLICY CLIENTS – MANDATED REGULATORY CHANGES
FROM: COMPLIANCE DEPARTMENT
SUBJECT: DOT PANEL REVISION
DATE: DECEMBER 1, 2017

Please be advised that effective January 1, 2018, the DOT testing panel will be adjusted to include expanded opioids. This change is intended to maintain consistency with new regulations established by the Department of Transportation (DOT) on November 10 that modify 49 CFR Part 40 of DOT (Part 40) drug testing programs. The revised panel is listed below.

Our laboratory partners are aware of this change, and we have worked closely with them to ensure a smooth transition to the new panel.

NOTE: There may be instances where collections occur prior to January 1st, but the actual laboratory analysis happens on or after that date. In these instances, the tests will be conducted under the new panel. Also, older Custody and Control Forms (CCF) can still be used until June 30, 2018.

In addition please make your employees aware of this change and provide them with the updated policy.

Expanded Opioids Include:

- Hydrocodone
- Oxycodone
- Hydromorphone
- Oxymorphone

Key Takeaways:

- DOT testing will include expanded opioids on January 1, 2018
- Older CCF forms can still be used until June 30, 2018